Feedback
Settings

Settings

Goto Application

2,536 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(HXVKEKIORVUWDR-FDDDBJFASA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 254
1.WO/2025/128901CIRCULAR RNA MOLECULES
WO - 19.06.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2024/059894 Applicant ARCTURUS THERAPEUTICS, INC. Inventor CHIVUKULA, Padmanabh
Provided herein are compositions and methods comprising a circular RNA that expresses an RNA-encoded polypeptide. Also provided herein are reaction mixtures i) comprising a DNA-dependent RNA polymerase, a plurality of nucleotide triphosphates, and a transcription template encoding an RNA and ii) an RNA and a ligase to produce a circular DNA.
2.WO/2025/129186CLOSTRIDIOIDES DIFFICILE VACCINE AND METHODS OF USE
WO - 19.06.2025
Int.Class A61K 39/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
08Clostridium, e.g. Clostridium tetani
 Appl.No PCT/US2024/060394 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor ALAMEH, Mohamad
The present disclosure provides compositions (e.g., pharmaceutical compositions, e.g., RNA-LNP vaccines) for delivery of C. difficile antigens and related technologies (e.g., components thereof and/or methods relating thereto).
3.WO/2025/129157GENE THERAPY FOR TREATMENT OF CANAVAN DISEASE
WO - 19.06.2025
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/US2024/060265 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor HORDEAUX, Juliette
Compositions and methods for treatment of Canavan disease are provided. The compositions include recombinant adeno-associated virus (rAAV) vectors, lipid nanoparticles, a recombinant nucleic acid molecules having a nucleotide sequence encoding a functional aspartoacylase (ASPA). In one embodiment, the recombinant adeno-associated virus (rAAV) comprises an adeno-associated virus (AAV) capsid and a vector genome packaged therein, wherein the vector genome comprises an expression cassette comprising one or more regulatory sequences operably linked to a nucleotide sequence encoding a functional aspartoacylase (ASPA), and wherein the nucleotide sequence encoding the functional ASPA is SEQ ID NO: 1 or a nucleotide sequence at least 99% identical to SEQ ID NO: 1.
4.WO/2025/129106IMMUNOEVASIVE TARGETING MOLECULES FOR EFFICIENT TARGETED DELIVERY
WO - 19.06.2025
Int.Class A61K 47/59
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
 Appl.No PCT/US2024/060185 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor PAPP, Tyler
The present invention relates to compositions and methods for effective delivery of a therapeutic agent to a subject using a delivery vehicle comprising a fusion construct comprising a targeting domain and a domain for evasion of the immune system. In some embodiments, the present invention relates to compositions and methods for targeted delivery of a therapeutic agent to a subject using a delivery vehicle comprising a fusion construct comprising a targeting domain for a specific cell type and a domain for evasion of the immune system. The invention also relates to methods of use of the compositions of the invention for the treatment of diseases and disorders, including the treatment of diseases and disorders in subjects having an inflammatory or autoimmune disease or disorder.
5.WO/2025/126019RNA MOLECULES
WO - 19.06.2025
Int.Class A61K 39/095
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
095Neisseria
 Appl.No PCT/IB2024/062402 Applicant PFIZER INC. Inventor MCMONAGLE, Patricia Michele
The present disclosure relates to RNA molecules encoding a Neisseria meningitidis polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of meningococcal disease.
6.WO/2025/123083DIAGNOSTIC APTAMER
WO - 19.06.2025
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
 Appl.No PCT/AU2024/051336 Applicant ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY Inventor BANSAL, Vipul
The present disclosure relates to the field of aptamers. More particularly, the present disclosure relates to aptamers for the specific binding of Group B Streptococcal (GBS) bacteria, such as Streptococcus agalactiae. Additionally, this disclosure relates to methods of using such aptamers in diagnosing, monitoring or treating diseases, disorders or conditions associated with GBS in patients.
7.WO/2025/126071RNA MOLECULES
WO - 19.06.2025
Int.Class C12N 15/67
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
67General methods for enhancing the expression
 Appl.No PCT/IB2024/062510 Applicant PFIZER INC. Inventor BENNETT, Eric Matthew
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
8.WO/2025/119162METAPNEUMOVIRUS (MPV) VACCINE
WO - 12.06.2025
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
 Appl.No PCT/CN2024/136380 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided is a metapneumovirus (MPV) vaccine. Specifically, provided is a nucleic acid comprising a polynucleotide for encoding a mutant of an MPV F protein, compared with a wild-type MPV F protein, the mutant comprises a disulfide bond mutation.
9.20250188132NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV)
US - 12.06.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No 18927762 Applicant ModernaTX, Inc. Inventor Giuseppe Ciaramella

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

10.20250186546Compositions and Methods to Prevent, Inhibit or Treat Autoimmune and Vascular Disease
US - 12.06.2025
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No 18747983 Applicant Katherine R. CROCE Inventor Katherine R. CROCE

Provided here are methods to prevent, inhibit or treat an autoimmune disease or a vascular or cardiovascular disorder in a mammal, comprising administering to the mammal a composition comprising an effective amount of isolated nucleic acid comprising a nucleotide sequence encoding WDFY3/Alfy or a portion thereof, a nucleotide sequence comprising a WDFY3/Alfy-specific long non-coding RNA (lncRNA) or a corresponding DNA sequence, a nucleotide sequence comprising a portion of a lncRNA WDFY3-AS2 or a corresponding DNA sequence, or isolated WDFY3/Alfy or a portion thereof.

# -